Gene expression of PBMC and isolated CD4 T cells from participants in Part A REDUC clinical trial
Ontology highlight
ABSTRACT: REDUC Part A (NCT02092116) assessed the effect of romidepsin in ART-treated chronically HIV-1 infected individuals. Here, we studied the gene expression on PBMCs or isolated CD4 before and after the 3-cycle infusion of Romidepsin
ORGANISM(S): Homo sapiens
PROVIDER: GSE185027 | GEO | 2022/03/28
REPOSITORIES: GEO
ACCESS DATA